Shanghai - Delayed Quote CNY

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS)

69.59
+0.06
+(0.09%)
At close: May 16 at 3:00:02 PM GMT+8
Loading Chart for 688399.SS
  • Previous Close 69.53
  • Open 70.00
  • Bid 69.59 x --
  • Ask 69.60 x --
  • Day's Range 68.88 - 70.88
  • 52 Week Range 57.32 - 105.15
  • Volume 284,779
  • Avg. Volume 722,405
  • Market Cap (intraday) 3.944B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.48
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 30, 2022
  • 1y Target Est --

Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. It offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. The company was founded in 2010 and is headquartered in Taizhou, China.

www.s-sbio.com

592

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688399.SS

View More

Performance Overview: 688399.SS

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688399.SS
5.89%
SSE Composite Index (000001.SS)
0.47%

1-Year Return

688399.SS
4.76%
SSE Composite Index (000001.SS)
7.85%

3-Year Return

688399.SS
45.76%
SSE Composite Index (000001.SS)
9.56%

5-Year Return

688399.SS
55.77%
SSE Composite Index (000001.SS)
17.40%

Compare To: 688399.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688399.SS

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    3.94B

  • Enterprise Value

    2.36B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.10

  • Price/Book (mrq)

    1.21

  • Enterprise Value/Revenue

    6.75

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.35%

  • Return on Assets (ttm)

    -1.59%

  • Return on Equity (ttm)

    -0.87%

  • Revenue (ttm)

    350.1M

  • Net Income Avi to Common (ttm)

    -29.25M

  • Diluted EPS (ttm)

    -0.48

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.96B

  • Total Debt/Equity (mrq)

    11.58%

  • Levered Free Cash Flow (ttm)

    4.88M

Research Analysis: 688399.SS

View More

Company Insights: 688399.SS

Research Reports: 688399.SS

View More

People Also Watch